Study of ASP0739 Alone and with Pembrolizumab in Advanced Solid Tumors with NY-ESO-1 Expression Participants

Trial Identifier: 0739-CL-0101
Sponsor: Astellas Pharma Global Development, Inc.
Start Date: December 2021
Primary Completion Date: June 2023
Study Completion Date: June 2023
Condition: Lung Cancer; Ovarian Cancer; Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States of America, CA Duarte, CA, United States of America, 91010
United States of America, FL Miami, FL, United States of America, 33136
United States of America, IL Chicago, IL, United States of America, 60637
United States of America, IL Chicago, IL, United States of America, 60611
United States of America, NY New York, NY, United States of America, 10016
United States of America, RI Providence, RI, United States of America, 02903